Home/ADHD, Medication, Research/Results from Phase II study with new ADHD drug

Results from Phase II study with new ADHD drug

ABT-894 is a drug that is currently undergoing clinical trials for possible approval by the FDA for the treatment of adult ADHD.  Drugs have to undergo specific study phases and must demonstrate safety and efficacy before they are approved by the FDA. 

ABT-894 is a neuronal nictotinic receptor (NNR) modulator.  NNRs modulate the release of neurotransmitters such as acetylcholine and dopamine.

ABT-894 was found to be effective in treating adult ADHD.  It appeared to be safe, well-tolerated, and had statistically significant efficacy compared to placebo. 

http://www.ad-hoc-news.de/drucken.html?art_id=17788204

Go to www.clinicaltrials.gov for a listing of all enrolling clinical trials.  You can also find ADHD clinical trials directly by clicking here: http://clinicaltrials.gov/ct2/results?cond=%22ADHD%22

By | 2016-10-05T06:46:13+00:00 June 20th, 2008|Categories: ADHD, Medication, Research|Tags: , , , , , , , , , |Comments Off on Results from Phase II study with new ADHD drug

About the Author:

Dr. Stephanie Sarkis is a National Certified Counselor (NCC), Licensed Mental Health Counselor (LMHC), and AMHCA Diplomate and Clinical Specialist in Child and Adolescent Counseling based in Tampa Bay, Florida, where she specializes in the treatment of ADD/ADHD. Dr. Sarkis conducts evaluations, testing, diagnosis, and counseling services. She also is a public speaker, consultant, coach, and is a facilitator in collaborative law.